¿¬±¸¼¾ÅÍ > ¿¬±¸¼¾ÅÍ
º» ¼¾ÅÍ´Â °¡Àå ´ëÇ¥ÀûÀΠȣÈí±â ÁúȯÀÎ Æó¾Ï, °áÇÙ ¹× ±âµµ Áúȯ, ÁßȯÀÚ °ü¸® ºÐ¾ß¿¡¼ Ȱ¹ßÇÑ ¿¬±¸ Ȱµ¿À» ÁøÇà ÁßÀ̸ç ÇâÈÄ Ãß°¡ÀûÀÎ ¿¬±¸ Ȱµ¿À» °èȹ ÁßÀÌ´Ù.
Æó¾ÏÀº Àü ¼¼°èÀûÀ¸·Î ¾Ï »ç¸Á·üÀÇ ¼öÀ§¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, Á¶±â Áø´Ü°ú Ä¡·á ¹æ¹ýÀÇ Çâ»ó¿¡µµ ºÒ±¸Çϰí ÀüüÀûÀÎ 5³â »ýÁ¸À²Àº ³·À¸¸ç (15%) Àç¹ß·üÀÌ ³ôÀº °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÌ¿Í °ü·ÃÇÏ¿© º» ¼¾ÅÍ¿¡¼´Â ´ÙÀ½°ú °°Àº ¿¬±¸¸¦ ÁøÇà ÁßÀÌ´Ù.
ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¼ Á¾¾ç³» Àú»ê¼Òȯ°æÀ¸·Î À¯µµµÈ HIF-1a¿Í microRNAs ¹ßÇöÀÇ »ó°ü °ü°è
ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ Á¾¾ç ¹ß»ý ¹× ÁøÇà °úÁ¤¿¡¼
Àú»ê¼Òȯ°æÀ¸·Î À¯µµµÈ HIF-1a¿Í ƯÁ¤ microRNAs ¹ßÇöÀ»
in vitro ½ÇÇèÀ¸·Î Áõ¸íÇϰí,
Áõ¸íµÈ microRNA¿Í ¼ö¼ú·Î ÀûÃâµÈ Á¾¾çÁ¶Á÷¿¡¼
¹ßÇöµÈ HIF-1a¿ÍÀÇ »óÈ£Á¶Àý °ü°è¸¦ ¹àÈ÷±â À§ÇÑ ¿¬±¸ÀÌ´Ù.
¸»Ãʼº Æó¾ÏÀÇ Á¶±âÁø´ÜÀ» À§ÇÑ À¯µµ°´´ãÀÇ È¿¿ë¼º
ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¼ EGFR mutation°ú miRNAsÀÇ »ó°ü °ü°è
ÇöÀç ¿ì¸®³ª¶ó´Â °áÇÙ ¹ß»ý·üÀÌ OECD ±¹°¡ Áß 1À§·Î °áÇÙ ÅðÄ¡¸¦ À§ÇÑ ³ë·ÂÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, º» ¼¾ÅÍ ¿ª½Ã °áÇÙ°ú °ü·ÃµÈ ´Ù¾çÇÑ ÁÖÁ¦·Î ¿¬±¸ Ȱµ¿À» ÁøÇà, °èȹÇϰí ÀÖ´Ù.
Diagnosic utility of ELISPO assay using induced sputum for rapid diagnosis of pulmonary tuberculosis
Comparision of diagnostic yield fo induced sputum with bronchoscopy in active pulmonary tuberculosis
The usefulness of rapid drug susceptibility test in antituberculous treatment
Clinical usefulness of tumor necrosis factor receptor for diagnosis of pulmonary tuberculosis
Diagnostic usefulness of enzymatic lysophophatidylcholine(LPC) in severe pneumonia
Comparison between high-flow nasal cannula system and conventional oxygen delivery system in acute
hypoxemic respiratory failure